474 First-in-class anti-PVR mAb NTX1088 restores expression of DNAM1 and augments antitumor immunity

BackgroundPoliovirus receptor (PVR, CD155) is a novel oncology target, differentially overexpressed in a wide range of solid tumors, which recently emerged as a main resistance mechanism to approved immune checkpoint inhibitors (ICIs). It is a key regulator of immune activation, that modifies functi...

Full description

Saved in:
Bibliographic Details
Published inJournal for immunotherapy of cancer Vol. 10; no. Suppl 2; p. A494
Main Authors Obeidat, Akram, Atieh, Anas, Vitenshtein, Alon, Cinamon, Guy, Paz, Keren, Roviš, Tihana, Brilc, Paola, Hirsl, Lea, Mandelboim, Ofer, Jonjic, Stipan, Pini Tsukerman
Format Journal Article
LanguageEnglish
Published London BMJ Publishing Group LTD 01.11.2022
Subjects
Online AccessGet full text

Cover

Loading…